Cell Metab March 2022 PMID 35235774

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.

Brage Brakedal, Christian Dölle, Frank Riemer, Yilong Ma, Gonzalo S Nido, Geir Olve Skeie, Alexander R Craven, Thomas Schwarzlmüller, Njål Brekke, Joseph Diab, Lars Sverkeli, Vivian Skjeie, Kristin Varhaug, Ole-Bjørn Tysnes, Shichun Peng

Download social card

Mentions

134

Peak: 64 in Mar 2022

across 7 sources since Mar 2022

Extended reach

740,371

potential audience

Total likes

296

Video views

1,763

Mentions per month

Mar 2022 – Aug 2025

Where it's discussed

X / Twitter89 posts
News29 articles
Blogs6 articles
Facebook4 posts
Reddit4 posts
Bluesky1 posts
YouTube1 videos

AI synopsis

What people are saying

Several discussions highlight key findings from the NADPARK study, such as the mention of increased NAD levels and mild clinical improvements. For instance, users expressed sentiments like 'promising results' and noted the 'first small positive result in human Parkinson's,' employing a tone that conveys cautious optimism. However, some posts raised concerns about data interpretation, using phrases like 'disappointing that...' which reflects a nuanced perspective on the study's outcomes.

AgreementModerate agreement

The majority of discussions generally express support for the findings of the NADPARK study, although some posts voice skepticism about the study's efficacy.

InterestHigh interest

There is a high level of curiosity surrounding the topic, with many individuals engaging with the research and its implications for Parkinson's treatment.

EngagementModerate engagement

While some posts provide detailed analysis and reference methodology, others show a more surface-level engagement with the results.

ImpactModerate impact

Although there is some optimism about the potential applications of nicotinamide riboside, a portion of discussions suggests a belief that the overall significance may be limited.

Abstract in brief

We conducted a phase I clinical trial to assess the safety and efficacy of nicotinamide riboside (NR) for boosting NAD levels in Parkinson's disease patients.
NR treatment was well tolerated, leading to a significant increase in cerebral NAD levels and associated metabolic changes, which correlated with mild clinical improvements.
The study suggests that NR may offer neuroprotective benefits for Parkinson's disease, highlighting the need for further research.

Read the full abstract

All mentions

Comparing NMN and NR Supplements for Healthy Aging

This video explores the growing interest in NMN and NR supplements and their potential benefits. Focused on scientific findings, it examines which supplement may be more effective for boosting NAD levels and the…

nuo life - Longevity · Aug 8, 2024 1,763 views

Tim Pierotti

@timpierotti1 · X

@MurgesJohn https://t.co/RksE2zNhpi - promising results from an NAD Precursor

Aug 11, 2025 · 1 like · 1,117 followers View post →

Tsunaki@中村健康科学研究所

@TsunakiNakamura · X

NADPARK 研究: パーキンソン病におけるニコチンアミドリボシド補給のランダム化第 I 相試験「私たちの研究結果は、ニコチンアミドリポシドが PD の潜在的な神経保護療法であると示唆しており、より大規模な試験でさらに調査する必要があることを示しています。」 https://t.co/6qzLQK1Ebw

Sep 16, 2024 · 3 likes · 3,498 followers View post →

Charles Brenner, PhD

@CharlesMBrenner · X

RT @Kevin_J_Collins: @AlexJLeaf @CharlesMBrenner https://t.co/6Wg2vS5oxR

Jun 7, 2023 · 1 share · 57,031 followers View post →

Jonestown

@Kevin_J_Collins · X

@AlexJLeaf @CharlesMBrenner https://t.co/6Wg2vS5oxR

Jun 7, 2023 · 3 likes · 1 share · 25 followers View post →

ぽん

@yasu0804 · X

Feb 4, 2023 · 14 likes · 4,471 followers View post →

Charles Brenner, PhD

@CharlesMBrenner · X

@kanonb05 mean age was 63 https://t.co/12nSJEmeav

Nov 29, 2022 · 2 likes · 57,031 followers View post →

Roland Baker

@RolandBakerIII · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/mxl1MnoUQk

Nov 13, 2022 · 3 likes · 8,165 followers View post →

Charles Brenner, PhD

@CharlesMBrenner · X

@LeveneDarren there are mouse data on protection against diabetic neuropathy from my lab since '16 lots of rodent data in chemo-neuropathy & central neuroprotection as well 1st small positive result in human Parkinson's is out more trials in process https://t.co/y19UnOglKv

Nov 4, 2022 · 3 likes · 57,031 followers View post →

Suzanne Peterson

@SuzannePeterso3 · X

RT @drmikehart: A randomized controlled trial on NAD+ boosting supplement Nicotinamide ribonucleoside (NR) has concluded that NR may effect…

Jun 29, 2022 · 1 share · 2,900 followers View post →

Mike Hart, M.D

@drmikehart · X

A randomized controlled trial on NAD+ boosting supplement Nicotinamide ribonucleoside (NR) has concluded that NR may effectively treat symptoms of Parkinson's disease. https://t.co/R9BZvRfjOy

Jun 29, 2022 · 10 likes · 1 share · 66,390 followers View post →

Morro Touray

@MMLTouray · X

RT @MichaelOkun: Phase I double blind study of NAD in Parkinson: "Boosting cellular levels nicotinamide adenine dinucleotide may confer neu…

Jun 11, 2022 · 2 shares · 578 followers View post →

Scorpion Doc

@ScorpionDoc3 · X

RT @MichaelOkun: Phase I double blind study of NAD in Parkinson: "Boosting cellular levels nicotinamide adenine dinucleotide may confer neu…

Jun 11, 2022 · 2 shares · 45 followers View post →

Michael Okun

@michaelokun.bsky.social · Bluesky

https://pubmed.ncbi.nlm.nih.gov/35235774/

Jun 11, 2022 View post →

Michael Okun

@MichaelOkun · X

Jun 11, 2022 · 12 likes · 2 shares · 38,524 followers View post →

Metabolic Monster

@Metabolicmonstr · X

Niacinamide riboside for Parkinson's treatment. Dosage =1000mg daily Can be achieved by the same amount of regular niacinamide / B3 https://t.co/ahbobyNO90 https://t.co/OISRMxGPNs

Jun 3, 2022 · 1 like · 2,363 followers View post →

Andreea Nitescu RD MSc

@AndreeaNRD · X

▪️ impacts cerebral metabolism in Parkinson's disease

May 29, 2022 · 3 likes · 1,283 followers View post →

Altamiro Bottino

@BottinoAltamiro · X

Targeting the brain's energy metabolism may hold the key for treating Parkinson's disease https://t.co/laD1edOj77 https://t.co/HRX51rgGYZ https://t.co/mxCwhH1wht

May 21, 2022 · 93 followers View post →

DrRPalmquist

@DrPalmquist · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease: Cell Metabolism https://t.co/M6tGorIfUm

May 15, 2022 · 1 like · 3,167 followers View post →

BrainEnergyMetabolism

@BrainMetabolism · X

Trial of nicotinamide riboside supplementation in #Parkinsons. Increased brain NAD+ in 10/15, increased glucose metabolism in those with ⬆️NAD+, ⬇️ inflammatory cytokines and mild improvement in clinical symptoms. https://t.co/9yStXUNUrP https://t.co/vER1S80ayp

Apr 25, 2022 · 7 likes · 1,249 followers View post →

simaxiaoer

@Simao70053701 · X

RT @Cell_Metabolism: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://…

Apr 23, 2022 · 3 shares · 7 followers View post →

Nature Aging

@NatureAging · X

RT @NatureAging: In @Cell_Metabolism “The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s…

Apr 22, 2022 · 3 shares · 18,671 followers View post →

Actavis

@ActavisPL · X

RT @raphaels7: https://t.co/1Txfv7Ic1k disappointing that nicotinamide riboside supplementation in Parkinson's disease patients didn't tran…

Apr 21, 2022 · 1 share · 398 followers View post →

Raphael Sirtoli

@raphaels7 · X

https://t.co/1Txfv7Ic1k disappointing that nicotinamide riboside supplementation in Parkinson's disease patients didn't translate to improved clinical motor symptoms NAD is more NAD levels?

Apr 21, 2022 · 3 likes · 1 share · 8,585 followers View post →

Dieter

@Wuhle · X

RT @NatureAging: In @Cell_Metabolism “The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s…

Apr 20, 2022 · 3 shares · 484 followers View post →

István Fodor

@fodor_i · X

RT @NatureAging: In @Cell_Metabolism “The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s…

Apr 19, 2022 · 3 shares · 545 followers View post →

Nature Aging

@NatureAging · X

In @Cell_Metabolism “The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease” https://t.co/wJFqErXPNl

Apr 19, 2022 · 23 likes · 3 shares · 18,671 followers View post →

Elena Becker-Barroso

@beckerbarroso · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside... https://t.co/mQdmIgQkW9

Mar 20, 2022 · 6 likes · 977 followers View post →

Jonas Thue Treebak

@treebak · X

Wake up editors/reviewers! Really a shame that the authors on this paper got away with performing t-tests and Wilcoxon tests on the data. The data analysis clearly confounds the interpretation and should be redone! https://t.co/47UqFNjqln

Mar 18, 2022 · 1 like · 958 followers View post →

NeverGiveUpNeverGiveIn!

@gofastfreddie · X

RT @FinishALS: NR in Parkinson’s Disease. Possible implications for ALS. https://t.co/fsuA8U88iX

Mar 15, 2022 · 3 shares · 58 followers View post →

EndALS

@FinishALS · X

RT @FinishALS: NR in Parkinson’s Disease. Possible implications for ALS. https://t.co/fsuA8U88iX

Mar 15, 2022 · 3 shares · 2,476 followers View post →

Jamie Timmons

@metapredict · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 15, 2022 · 10 shares · 2,055 followers View post →

Fay

@fay90028966 · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 15, 2022 · 10 shares · 142 followers View post →

Erkan Guntore

@erkanguntore · X

RT @FinishALS: NR in Parkinson’s Disease. Possible implications for ALS. https://t.co/fsuA8U88iX

Mar 14, 2022 · 3 shares · 3,645 followers View post →

@mo_mo_taro_33 · X

RT @babataiki326: NADはパーキンソン病患者を救うか！？(Cell Metab) 新規診断の未治療PD患者30名を対象に、NR*経口投与 (1000 mg/day, 30 days)の第1相試験が行われた (NR=15 vs placebo=15)。NR投与…

Mar 5, 2022 · 3 shares · 36 followers View post →

JoaquimLamora

@JoaquimLamora · X

RT @UpToPhate: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/r…

Mar 5, 2022 · 1 share · 1,134 followers View post →

UpToPhate

@UpToPhate · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/rpRYN5YGTQ

Mar 5, 2022 · 1 like · 1 share · 195 followers View post →

しゃみ

@seimi_0501 · X

Mar 5, 2022 · 3 shares · 630 followers View post →

Taiki Baba

@babataiki326 · X

NADはパーキンソン病患者を救うか！？(Cell Metab) 新規診断の未治療PD患者30名を対象に、NR*経口投与 (1000 mg/day, 30 days)の第1相試験が行われた (NR=15 vs placebo=15)。NR投与でのNAD↑ & 炎症性サイトカイン↓ in 血清 & CSF、軽度の臨床的改善！ #2022年論文紹介63 https://t.co/MDd3SJsQpp

Mar 5, 2022 · 7 likes · 3 shares · 2,707 followers View post →

the paper link

@the_paper_link · X

Trend new: Brakedal B, ..., Tzoulis C (Cell Metab) __The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease__ https://t.co/4curiMxcgR

Mar 5, 2022 · 137 followers View post →

Amy Lamotte

@amylamotte88 · X

RT @agingdoc1: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/…

Mar 4, 2022 · 2 shares · 259 followers View post →

Sunset HQ

@SunsetHQBC · X

RT @Cell_Metabolism: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://…

Mar 3, 2022 · 3 shares · 15 followers View post →

Alleo Labs

@alleolabs · X

RT @ad_papers: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab #A…

Mar 3, 2022 · 1 share · 180 followers View post →

Mattia Quattrocelli

@mattiaquattro · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/4BVl5dYu0B of note: clinical trial with NR, 31P MRS and 18FDG PET in brains and cerebrospinal fluid, transcriptomics and metabolomics in blood and muscle

Mar 3, 2022 · 7 likes · 1,739 followers View post →

Punkmando (dr house's evil twin)

@Punkmando1 · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 3, 2022 · 10 shares · 268 followers View post →

Agingdoc

@agingdoc1 · X

RT @agingdoc1: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/…

Mar 3, 2022 · 2 shares · 41,492 followers View post →

Robin H. Gunster

@rhg_1 · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 3, 2022 · 7 shares · 631 followers View post →

Kelly A. Hogan Ph.D.

@Loose_Lab_Rat · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/NXNwqjtCUm

Mar 3, 2022 · 2,240 followers View post →

Bioinformatics Trends 

@BinfoTrends · X

RT @Metabbot: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab #me…

Mar 3, 2022 · 1 share · 8,157 followers View post →

Vitas Gerulaitis

@VGerulaitis · X

RT @nick_krontiris: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease (open acc…

Mar 3, 2022 · 4 shares · 155 followers View post →

Metabolomics Papers

@Metabbot · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab #metabolomics https://t.co/Xo0cDQKI8L

Mar 3, 2022 · 1 like · 1 share · 1,488 followers View post →

The Scheibye-Knudsen Lab

@ScheibyeKnudsen · X

RT @Cell_Metabolism: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://…

Mar 3, 2022 · 3 shares · 1,706 followers View post →

Orlando_uy

@Orlando_uy · X

RT @nick_krontiris: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease (open acc…

Mar 3, 2022 · 4 shares · 692 followers View post →

Cell Metabolism

@Cell_Metabolism · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/WCLuHXeS32

Mar 3, 2022 · 16 likes · 3 shares · 53,679 followers View post →

Nick Krontiris

@nick_krontiris · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease (open access) https://t.co/UzOAUE6udu https://t.co/5KEbhic1Wm

Mar 3, 2022 · 10 likes · 4 shares · 19,033 followers View post →

MR Spectroscopy (MRS)

@mr_spectroscopy · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/z19ozyect4 https://t.co/Qw1LCfjaKw

Mar 3, 2022 · 558 followers View post →

mitopapers

@mito_papers · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/7GUJs0R9nI https://t.co/TBhPt7mu66

Mar 3, 2022 · 145 followers View post →

AD_papers

@ad_papers · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab #Alzheimers https://t.co/56XnCWw46r

Mar 3, 2022 · 1 like · 1 share · 151 followers View post →

Kevin C. Klatt, PhD, RD

@KCKlatt · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 3, 2022 · 10 shares · 21,099 followers View post →

Paperbirds_Neurology

@PaperbirdsN · X

New article: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease https://t.co/Sft0KG0cW2 #parkinsons #neurology https://t.co/eqFs18vlRG

Mar 3, 2022 · 457 followers View post →

I. Lastres-Becker lab

@Isalabe13 · X

RT @ScienceofPD: Wow - @brage_ @chtzoulis & colleagues present the results of the NADPARK study: A randomized phase I trial of nicotinamide…

Mar 3, 2022 · 4 shares · 812 followers View post →

Matías Monsalves-Álvarez

@profemonsalves · X

RT @r_calv: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/ZDp…

Mar 2, 2022 · 1 share · 1,507 followers View post →

Sean

@Sean10080620 · X

RT @jorgensenmc1: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease: Cell Metab…

Mar 2, 2022 · 1 share · 437 followers View post →

Teri

@blondenaturel · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 12 followers View post →

Riccardo Calvani

@r_calv · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/ZDpQiBdziN

Mar 2, 2022 · 3 likes · 1 share · 1,096 followers View post →

Javier Díaz-Nido

@Javier_DiazNido · X

RT @ScienceofPD: Wow - @brage_ @chtzoulis & colleagues present the results of the NADPARK study: A randomized phase I trial of nicotinamide…

Mar 2, 2022 · 4 shares · 1,839 followers View post →

Conner34

@Conner3412 · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 12 followers View post →

Nabil Djouder

@NabilDjouder · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 426 followers View post →

Bill Walker

@BWalkerTTAGGG · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 1,363 followers View post →

The Canadian Open Parkinson Network

@copn_rpco · X

RT @ScienceofPD: Wow - @brage_ @chtzoulis & colleagues present the results of the NADPARK study: A randomized phase I trial of nicotinamide…

Mar 2, 2022 · 4 shares · 178 followers View post →

Charles Jourdan Reyes, Ph.D.

@reyes_jourdan · X

RT @ScienceofPD: Wow - @brage_ @chtzoulis & colleagues present the results of the NADPARK study: A randomized phase I trial of nicotinamide…

Mar 2, 2022 · 4 shares · 624 followers View post →

Agingdoc

@agingdoc1 · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/ki11nc5snb

Mar 2, 2022 · 5 likes · 2 shares · 41,492 followers View post →

Kei Sakamoto

@Kei__Sakamoto · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 1,580 followers View post →

CogniSphere

@jorgensenmc1 · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease: Cell Metabolism https://t.co/FC2IVge0cH

Mar 2, 2022 · 2 likes · 1 share · 814 followers View post →

Jonathan Sebat

@sebatlab · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 2, 2022 · 7 shares · 4,999 followers View post →

Nicola Marino

@nikmarino9 · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/cWt3JxKCqY

Mar 2, 2022 · 2 likes · 8,777 followers View post →

Orlando_uy

@Orlando_uy · X

RT @CharlesMBrenner: positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 10 shares · 692 followers View post →

Charles Brenner, PhD

@CharlesMBrenner · X

positive results in small NR phase I trial for Parkinson’s disease. larger trial started https://t.co/6ckMM8bVN7

Mar 2, 2022 · 65 likes · 10 shares · 57,031 followers View post →

Gary J. He, PhD

@GARY_J_HE · X

RT @Padraig1991: @CharlesMBrenner Non-relevant. I’m sure you’re read it. But being that you are the one who discovered NR as a NAD precurso…

Mar 2, 2022 · 2 shares · 59 followers View post →

Charles Brenner, PhD

@CharlesMBrenner · X

RT @Padraig1991: @CharlesMBrenner Non-relevant. I’m sure you’re read it. But being that you are the one who discovered NR as a NAD precurso…

Mar 2, 2022 · 2 shares · 57,031 followers View post →

john morley

@drjohnmorley · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside... https://t.co/U6TzlIFCIz

Mar 2, 2022 · 3 likes · 8,321 followers View post →

The Science of Parkinson's

@ScienceofPD · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 2, 2022 · 7 shares · 10,891 followers View post →

K Patrick Waldron Gr

@Padraig1991 · X

@CharlesMBrenner Non-relevant. I’m sure you’re read it. But being that you are the one who discovered NR as a NAD precursor I thought I might share with you anyhow :) https://t.co/xtE5151zGL

Mar 2, 2022 · 5 likes · 2 shares · 323 followers View post →

The Science of Parkinson's

@ScienceofPD · X

Wow - @brage_ @chtzoulis & colleagues present the results of the NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in #Parkinsons; This was a small pilot (n=30) to the current NOPARK study; Oral NR⬆️brain NAD levels https://t.co/D90aNwm5fR https://t.co/nTvjsDOqjQ

Mar 2, 2022 · 10 likes · 4 shares · 10,891 followers View post →

FDick

@FDick91 · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 2, 2022 · 7 shares · 9 followers View post →

TimePie (focus on anti-aging science)

@TimePieChina · X

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/scWLJngpkp 帕金森患者接受30天1000毫克NR治疗后，大脑中的NAD+水平提高，帕金森症状改善。其中9名患者表现出超过基线水平10%的变化。

Mar 2, 2022 · 691 followers View post →

Rene Sugar

@renesugar · X

Targeting the brain’s energy metabolism may hold the key for treating Parkinson’s disease https://t.co/KhHNmOiqD6 The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/Yr8M9rEmbC

Mar 1, 2022 · 3,959 followers View post →

Gonzalo S. Nido

@GonzaloNido · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 1, 2022 · 7 shares · 55 followers View post →

Yamila Torres Cleuren

@YCleuren · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 1, 2022 · 7 shares · 52 followers View post →

Njål Lura

@Njaallura · X

RT @chtzoulis: Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplem…

Mar 1, 2022 · 7 shares · 177 followers View post →

Charalampos Tzoulis

@chtzoulis · X

Encouraging results from our phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease https://t.co/v6j6Clh9vR

Mar 1, 2022 · 20 likes · 7 shares · 295 followers View post →

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Comparing NMN and NR Supplements for Healthy Aging